NEJM with two early release articles. One by cardiologist Eric Topol, and the other questioning whether Celebrex and other COX-2′s have similar cardiovascular risk.
Related Stories
More in Uncategorized
Comments
Previous post: The repercussions of the flu vaccine shortage
Next post: CNN news, brought to you by Ambien
